{"id":873,"date":"2021-03-01T06:10:44","date_gmt":"2021-03-01T06:10:44","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=873"},"modified":"2021-03-01T06:10:44","modified_gmt":"2021-03-01T06:10:44","slug":"23-feb-2021-tocilizumab-methylprednisolone-showed-significant-impact-on-survival","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/23-feb-2021-tocilizumab-methylprednisolone-showed-significant-impact-on-survival\/","title":{"rendered":"(23 Feb 2021) Tocilizumab &#038; methylprednisolone- showed significant impact on survival"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: single center cohort study of 685 patients<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.jtauto.2021.100086<\/p>\n<p class=\"\">From March 3 rd to May 7 th, 685 patients were included for analysis (58.4% males, mean age 68.9 years). Patients in the first period (n=408) were younger (66.6 vs 71.1 years, p=0.003),presented lower mean P a O 2\/F i O2 ratio at admission (256.5 vs 270.4 mm Hg,p=0.0563), higher ferritin (1520 vs 1221 ng\/ml, p=0.01), higher IL-6 (679 vs 194 pg\/ml,p&lt;0.0001) and similar D-dimer levels (3.59 vs 3.39 mug\/mL, p=0.65) compared to the second period (n=277). Lopinavir\/ritonavir and interferon were preferentially given in the first period (23.8% and 32% vs 1.8% and 11.9%, p&lt;0.0001). Use of corticoids (88.2% vs 87.4%, p=0,74) and tocilizumab (26.29 vs 20.22% p=0.06) were similarly administered in both periods. Patients in the second period needed less mechanical ventilation (4.9% vs 16.9%, p&lt;0.0001), fewer ICU admission (6.1% vs 20.1%,p&lt;0.0001) and showed similar mortality (17.7% vs 15.4%, p=0.43). Infectious and thrombotic complications were comparable in both periods (both around 8%, with no statistical difference). Patients treated with tocilizumab (n=163) had lower mortality rate compared to those untreated under the same indication (7.9% vs 24.2%, p&lt;0.0001).In this large retrospective COVID-19 in-hospital cohort, lopinavir\/ritonavir and interferon showed no significant impact on survival. Extensive use of corticosteroids and tocilizumab resulted in good overall outcome and showed acceptable complication rates.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: single center cohort study of 685 patients https:\/\/doi.org\/10.1016\/j.jtauto.2021.100086 From March 3 rd to May 7 th, 685 patients were included for analysis (58.4% males, mean age 68.9 years). Patients&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/23-feb-2021-tocilizumab-methylprednisolone-showed-significant-impact-on-survival\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(23 Feb 2021) Tocilizumab &#038; methylprednisolone- showed significant impact on survival&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[51,4,18],"tags":[52,27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/873"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=873"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/873\/revisions"}],"predecessor-version":[{"id":874,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/873\/revisions\/874"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=873"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=873"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=873"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}